Extended Data Fig. 7: Replenishment in WT:GFP-puromycin-resistant chimeric organoids.
From: Cerebral organoids display dynamic clonal growth and tunable tissue replenishment
a-f, Immunofluorescent analysis of day 42 organoids chimeric for WT:GFP-puro (starting at 80:20 ratios) with (b, d, f) or without (a, c, e) puromycin treatment from day 11 on. Antibody labelling indicated in panels. g, qPCR analysis of various chimeric H9 WT and GFP-puromycin-resistant organoids (n = 6 organoids as biological replicates from 2 differentiation experiments). h-k, Whole organoid lineage tracing of WT:GFP-puro chimeric organoids. Lineage size distribution in conditions indicated on the top (h, 80% WT: 20% GFP-puro, no puromycin; i, 80% WT: 20% GFP-puro, with puromycin; j, 90% WT: 10% GFP-puro, no puromycin; k, 90% WT: 10% GFP-puro, with puromycin. (n = individual lineages from 3 organoids as biological replicates from 1 differentiation experiment at each time point for each ± puromycin treatment). l, Schematic of optimal transport and foldchange calculation.
